Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- Product Overview:
CD47 is a transmembrane protein and ligand for signal regulatory protein ? (SIRP?; Item No. 32082) with roles in phagocytosis, cell adhesion, and migration.{53811} It is composed of five transmembrane regions and a single immunoglobulin-like (Ig-like) domain that interacts with the amino terminus of SIRP? to induce inhibitory signaling and prevent phagocytosis. CD47 is expressed on all cells, including erythrocytes and platelets, but the levels of expression on immune cells fluctuates in an immune status- or disease-dependent manner. It interacts with certain integrins and functions as a receptor for the extracellular matrix protein thrombospondin. CD47 is overexpressed in various cancer cells, and anti-CD47 antibodies enhance macrophage phagocytosis of tumor cells in vitro.{53810} Cd47-/- mice exhibit defective mucosal repair after intestinal biopsy or intestinal mucosal damage induced by dextran sulfate sodium (DSS; Item No. 23250).{52622} Knockout of Cd47 also decreases infarct volume and hemispheric swelling in a mouse model of transient focal cerebral ischemia.{52621} It also decreases sensorimotor function deficits, brain lesion volume, and neutrophil infiltration, as well as increases brain blood vessel density in a mouse model of traumatic brain injury.{52623} Cayman’s CD47 (human, recombinant) protein can be used for ELISA. This protein consists of 132 amino acids, has a calculated molecular weight of 15.2 kDa, and a predicted N-terminus of Gln19 after signal peptide cleavage. By SDS-PAGE, under reducing conditions, the apparent molecular mass of the protein is approximately 40 kDa due to glycosylation.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.